Intanza® 9 μg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 115-121

  Leroux Roels, Isabel ^a   Weber, Francoise ^b  

^a GHENT UNIVERSITY   (Belgium)

^b SANOFI PASTEUR   (France)

Author keywords

Acceptability; Immunogenicity; Intradermal; Microinjection; Safety; Trivalent influenza vaccine

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

ADULT; AGE DISTRIBUTION; ARTHRALGIA; ASTHENIA; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EQUIPMENT DESIGN; HEALTH CARE COST; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALAISE; MICROINJECTION; MICROINJECTOR; MICRONEEDLE; MYALGIA; NONHUMAN; POSTMARKETING SURVEILLANCE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SIDE EFFECT; SWEATING; TREATMENT INDICATION;

ADOLESCENT; ADULT; EQUIPMENT AND SUPPLIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84874701771     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22342     Document Type: Review

References (62)

1. Monto AS. Seasonal influenza and vaccination coverage. Vaccine 2010; 28(Suppl 4):D33-44; PMID:20713259; http://dx.doi.org/10.1016/j.vaccine.2010.08. 027.
2. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza -United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62; PMID:20798667.
3. World Health Organization. Influenza (seasonal). Geneva: World Health Organization Media Centre, 2009.
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/ jama.289.2.179.
5. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283:499-505; PMID:10659876; http://dx.doi.org/10.1001/jama.283.4.499.
6. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986; 76:761-5; PMID:3717461; http://dx.doi.org/10.2105/AJPH.76.7.761.
7. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112:798-811; PMID:7457471.
8. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-82; PMID:10520648; http://dx.doi.org/10.1016/S0140-6736(99)01241-6.
9. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al.; US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283:1016-24; PMID:10697061; http://dx.doi.org/10. 1001/jama.283.8.1016.
10. Roche Pharmaceuticals. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000; 6(Suppl):S276-81; PMID:10977474.
11. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008; 26:911-24; PMID:18850761; http://dx.doi.org/10.2165/00019053-200826110-00004.
12. Arnoux S, Weinberger C, Gessner BD. Vaccinepreventable influenza disease burden from clinical trials of Vaxigrip -an inactivated split virion influenza vaccine -supports wider vaccine use. Vaccine 2007; 25:7720-31; PMID:17920168; http://dx.doi.org/10.1016/j.vaccine.2007.08.063.
13. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046.
14. Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health 2010; 10:724; PMID:21106057; http://dx.doi.org/10.1186/1471-2458-10-724.
15. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; CD001269; PMID:20614424.
16. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/ S1473-3099(11)70295-X.
17. Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010; 85:257-73; PMID:20118381; http://dx.doi.org/10.4065/mcp.2009.0615.
18. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655-63; PMID:11015795; http://dx.doi.org/10.1001/jama.284.13.1655.
19. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333:889-93; PMID:7666874; http://dx.doi.org/10.1056/ NEJM199510053331401.
20. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis 2009; 48:292-8; PMID:19115970; http://dx.doi.org/10.1086/595842.
21. Hak E, Buskens E, van Essen GA, de Bakker DH, Grobbee DE, Tacken MA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005; 165:274-80; PMID:15710789; http://dx.doi.org/10.1001/archinte.165.3.274.
22. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68-77; PMID:15639212; http://dx.doi.org/10.1016/j.amjmed.2004.03.044.
23. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62; PMID:20689501.
24. Centers for Disease Control. Healthy People 2020 Summary of Objectives. 2011.
25. Schabas RE. Mass influenza vaccination in Ontario: a sensible move. CMAJ 2001; 164:36-7; PMID:11202665.
26. World Health Organization. Resolution of the World Health Assembly WHA 56.19. Prevention and control of influenza pandemics and annual epidemics. 56th World Health Assembly. Geneva, 2003.
27. The Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union 2009; L348:71-2.
28. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58:446-58; PMID:19446340; http://dx.doi.org/10.1016/j.jinf.2009.04.001.
29. Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza vaccination coverage-United States, August 2010-February 2011. MMWR Morb Mortal Wkly Rep 2011; 60:737-43; PMID:21659982.
30. Kroneman MW, van Essen GA. Stagnating influenza vaccine coverage rates among high-risk groups in Poland and Sweden in 2003/4 and 2004/5. Euro Surveill 2007; 12:E1-2; PMID:17991383.
31. Müller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 2007; 35:308-19; PMID:17885730; http://dx.doi.org/10.1007/s15010-007-6218-5.
32. Madjid M, Alfred A, Sahai A, Conyers JL, Casscells SW. Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. Tex Heart Inst J 2009; 36:546-52; PMID:20069079.
33. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008; 121(Suppl 2):S28-35; PMID:18589065; http://dx.doi.org/10.1016/j. amjmed.2008.05.005.
34. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003; 68:341-4; PMID:12685642.
35. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8:272; PMID:18673545; http://dx.doi.org/10.1186/1471-2458-8-272.
36. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 g intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011; 28:640-9; PMID:21751080; http://dx.doi.org/10.1007/s12325-011-0042-0.
37. Prymula R, Usluer G, Altinel S, Sichova R, Weber F. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther 2012; 29:41-52; PMID:22228256; http://dx.doi.org/10.1007/ s12325-011-0090-5.
38. Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011; 7(Suppl):29-40; PMID:21245655; http://dx.doi.org/10.4161/hv.7.0.14560.
39. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26:3197-208; PMID:18486285; http://dx.doi.org/10.1016/j.vaccine.2008.03.095.
40. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin 2011; 7:811-27; PMID:21817854; http://dx.doi.org/10.4161/hv.7.8.16274.
41. Tuft L. Active immunization against typhoid fever with particular reference to an intradermal method. J Lab Clin Med 1931; 16:552.
42. Francis T, Magill TP. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med 1937; 65:251-9; PMID:19870599; http://dx.doi.org/10.1084/jem.65.2.251.
43. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14; PMID:18844594; http://dx.doi.org/10.1586/14760584.7.8.1201.
44. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11:415-27; PMID:21299438; http://dx.doi.org/10.15 17/14712598.2011.557658.
45. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000; 31(Suppl 3):S64-7; PMID:11010824; http://dx.doi.org/10.1086/314072.
46. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009; 333:369-93; PMID:19768415; http://dx.doi.org/10.1007/978-3-540-92165-3-18.
47. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-42; PMID:18023942; http://dx.doi.org/10.1016/j.vaccine.2007.10.020.
48. Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, Nicolas JF, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007; 25:6423-30; PMID:17640778; http://dx.doi.org/10. 1016/j.vaccine.2007.05.046.
49. Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine 2006; 24:1586-92; PMID:16271424; http://dx.doi.org/10.1016/j. vaccine.2005.10.008.
50. Atmar RL, Patel SM, Keitel WA. Intanza(®): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010; 9:1399-409; PMID:21105776; http://dx.doi.org/10.1586/erv.10.134.
51. Duggan ST, Plosker GL. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years). Drugs Aging 2010; 27:597-605; PMID:20583853; http://dx.doi.org/10.2165/11203880-000000000-00000.
52. Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012; 11:17-25; PMID:22149703; http://dx.doi.org/10.1586/erv.11.154.
53. Frenck RW Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http://dx.doi.org/10.1016/j.vaccine.2011.06.010.
54. Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products, 1997.
55. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; PMID:19341446; http://dx.doi.org/10.1186/1741-7015-7- 13.
56. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-9; PMID:18930093; http://dx.doi.org/10.1016/j.vaccine.2008.09.078.
57. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346-54; PMID:20372053; http://dx.doi.org/10.4161/hv.6. 4.10961.
58. European Medicines Agency. Assessment report for Intanza®. London: European Medicines Agency, 2009.
59. European Medicines Agency. Intanza 9 g summary of product characteristics. 2011.
60. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin 2010; 6:336-45; PMID:20372083; http://dx.doi.org/10.4161/hv.6.4.10753.
61. Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI) questionnaire. Health Qual Life Outcomes 2009; 7:21; PMID:19261173; http://dx.doi.org/10.1186/1477-7525-7-21.
62. Arnou R, Frank M, Hagel T, Prébet A. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Ther 2011; 28:555-65; PMID:21626269; http://dx.doi.org/10.1007/s12325-011-0035-z.